Patents Examined by Alana Harris Dent
  • Patent number: 12253524
    Abstract: Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1 complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: March 18, 2025
    Assignee: Albert Einstein College of Medicine
    Inventors: Harry Ostrer, Johnny C. Loke, Alexander Pearlman
  • Patent number: 12247973
    Abstract: The present invention is directed to a method for the diagnosis of cancer involving the plasma membrane citrate transporter (pmCiC). The invention is further directed to a modified substrate or modulator of pmCiC, the use of pmCiC as a tumor marker and a method of screening for a modulator of pmCiC activity.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: March 11, 2025
    Assignee: Universitätsklinikum Regensburg
    Inventors: Edward Geissler, Maria Mycielska, Petra Rümmele
  • Patent number: 12234288
    Abstract: The present invention relates to novel polypeptides, which are derived from Arginase2. The invention also concerns uses of the polypeptides and compositions comprising the polypeptides.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: February 25, 2025
    Assignee: IO Biotech ApS
    Inventor: Mads Hald Andersen
  • Patent number: 12226479
    Abstract: The subject matter disclosed herein is generally directed to CD8+ tumor infiltrating lymphocytes comprising gene signatures associated with response to immunotherapy treatment. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the gene signatures. Specifically, disclosed herein are gene signatures associated with response to checkpoint blockade therapy and immune cell subtypes characterized by said gene signatures. Further disclosed are methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs enriched for a specific subtype.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 18, 2025
    Assignees: The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Moshe Sade-Feldman, Keren Yizhak, Gad Getz, Nir Hacohen
  • Patent number: 12174191
    Abstract: A method of diagnosing pancreatic cancer in a patient by detecting a level of one or more glycoforms of a Lewis antigen and a level of the one or more glycoforms of MUC5AC. The patient diagnosed with pancreatic cancer then may be treated for this disease. Also, a method for detecting a level of a glycan in a sample which includes using a capture reagent to immobilize the glycan on a substrate; exposing the immobilized glycan to a detection reagent; detecting the level of the immobilized glycan; and combining the biological sample with one or more pre-capture enzymes and/or exposing the immobilized glycan to one or more pre-detection enzymes.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: December 24, 2024
    Assignees: VAN ANDEL RESEARCH INSTITUTE, UNIVERSITY OF PITTSBURGH
    Inventors: Brian B. Haab, Randall E. Brand
  • Patent number: 12171760
    Abstract: This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 24, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventor: Hazel Hunt
  • Patent number: 12161718
    Abstract: Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., ABRAXANE® nanoparticles) and antibodies. The compositions are used to effect hematologic cancer cell death.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: December 10, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 12157759
    Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: December 3, 2024
    Assignees: The UAB Research Foundation, HudsonAlpha Institute for Biotechnology
    Inventors: Katherine E Varley, Richard M Myers, Brian S Roberts, Jason Gertz, Donald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
  • Patent number: 12158399
    Abstract: Provided herein are compositions including a CaMKK2 inhibitor and an anti-cancer therapeutic agent and methods of treating cancer in a subject by administering a therapeutically effective amount of the composition to a subject. The subject may be selected for treatment based on an immune cell measurement of a sample from the subject. Methods of treating cancer by administering a therapeutically effective amount of a CaMKK2 inhibitor, and administering a therapeutically effective amount of an anti-cancer therapeutic agent to the subject are also provided. Kits including combination of a CaMKK2 inhibitor and another anti-cancer therapeutic agent are also provided.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 3, 2024
    Assignee: Duke University
    Inventors: Luigi Racioppi, Erik Nelson, Wei Huang, Nelson Chao, Donald McDonnell
  • Patent number: 12156905
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: December 3, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 12153041
    Abstract: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: November 26, 2024
    Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SE
    Inventors: Mathias Vormehr, Ugur Sahin, Barbara Schrörs, Martin Löwer, Sebastian Boegel
  • Patent number: 12123877
    Abstract: The application discloses CD321 as a useful global marker of circulating tumor cells (CTCs) and provides related methods and kits of parts relying on detection of CD321.5.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 22, 2024
    Assignee: UNIVERSITÉ LIBRE DE BRUXELLES
    Inventors: Cédric Blanpain, Panagiota Sotiropoulou, Ievgenia Pastushenko
  • Patent number: 12110340
    Abstract: A method for detecting cells having granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) or a fragment thereof is provided. The detection method may comprise: (a) contacting the cells with an effective amount of a binding protein, wherein the binding protein comprises an antigen binding fragment that specifically binds GASP-1; and (b) identifying cells having granules bound to the binding protein. The GASP-1 granules may be in the cytosol or on the surface of the cells. Also provided are methods for producing T-cells comprising a chimeric antigen receptor, anti-GASP-1 antibody or a bi-specific binding protein. Further provided are methods for treating GASP-1-mediated to disease or inactivating exosomes, microvesicles or oncosomes.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: October 8, 2024
    Assignee: Proplex Technologies, LLC
    Inventors: Frank N. Chang, George P. Tuszynski, Solomon Luo, Jeff Yang
  • Patent number: 12064413
    Abstract: The present invention provides methods and compositions for treating or preventing melanoma with S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: August 20, 2024
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Rong Li, Bin Yuan, Tyler Curiel
  • Patent number: 12054787
    Abstract: The present invention relates to gene expression signatures that predict response and resistance to targeted therapy and immunotherapy.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: August 6, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Xiaole Liu, Peng Jiang
  • Patent number: 12029785
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: July 9, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 12023372
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: July 2, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11975058
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: May 7, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11957742
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: April 16, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11951160
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: April 9, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh